2,144 research outputs found
Phosphoinositide lipids in primary cilia biology
Primary cilia are solitary signalling organelles projecting from the surface of most cell types. Although the ciliary membrane is continuous with the plasma membrane it exhibits a unique phospholipid composition, a feature essential for normal cilia formation and function. Recent studies have illustrated that distinct phosphoinositide lipid species localise to specific cilia subdomains, and have begun to build a 'phosphoinositide map' of the cilium. The abundance and localisation of phosphoinositides are tightly regulated by the opposing actions of lipid kinases and lipid phosphatases that have also been recently discovered at cilia. The critical role of phosphoinositides in cilia biology is highlighted by the devastating consequences of genetic defects in cilia-associated phosphoinositide regulatory enzymes leading to ciliopathy phenotypes in humans and experimental mouse and zebrafish models. Here we provide a general introduction to primary cilia and the roles phosphoinositides play in cilia biology. In addition to increasing our understanding of fundamental cilia biology, this rapidly expanding field may inform novel approaches to treat ciliopathy syndromes caused by deregulated phosphoinositide metabolism
Cracking the context-specific PI3K signaling code.
Specificity in signal transduction is determined by the ability of cells to âencodeâ and subsequently âdecodeâ different environmental signals. Akin to computer software, this âsignaling codeâ governs context-dependent execution of cellular programs through modulation of signaling dynamics and can be corrupted by disease-causing mutations. Class IA phosphoinositide 3-kinase (PI3K) signaling is critical for normal growth and development and is dysregulated in human disorders such as benign overgrowth syndromes, cancer, primary immune deficiency, and metabolic syndrome. Despite decades of PI3K research, understanding of context-dependent regulation of the PI3K pathway and of the underlying signaling code remains rudimentary. Here, we review current knowledge on context-specific PI3K signaling and how technological advances now make it possible to move from a qualitative to quantitative understanding of this pathway. Insight into how cellular PI3K signaling is encoded or decoded may open new avenues for rational pharmacological targeting of PI3K-associated diseases. The principles of PI3K context-dependent signal encoding and decoding described here are likely applicable to most, if not all, major cell signaling pathways
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to induce
tumor cell death is limited. The efficacy of PI3K inhibition can also derive from interference with
the cancer cellsâ ability to respond to stromal signals, as illustrated by the approved PI3KÎŽ
inhibitor Idelalisib in B-cell malignancies. Inhibition of the leukocyte-enriched PI3KÎŽ or PI3KÎł
may unleash more potent anti-tumor T-cell responses, by inhibiting regulatory T-cells and
immune-suppressive myeloid cells. Moreover, tumor angiogenesis may be targeted by PI3K
inhibitors to enhance cancer therapy. Future work should therefore focus on the effects of PI3K
inhibitors on the stroma, in addition to their direct effects on tumors.
SIGNIFICANCE: The PI3K pathway extends beyond the direct regulation of cancer cell
proliferation and survival. In B-cell malignancies, targeting PI3K purges the tumor cells from their
protective microenvironment. Moreover, we propose that PI3K isoform-selective inhibitors may be
exploited in the context of cancer immunotherapy and by targeting angiogenesis to improve drug
and immune cell deliver
Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
The PI3K p110α isoform regulates endothelial adherens junctions via Pyk2 and Rac1
Only the p110α isoform of PI3K mediates the association of VE-cadherin with Pyk2, a Rac GEF and the p85 PI3K regulatory subunit, to reduce junctional integrity in response to TNF
Autocrine tumor necrosis factor (TNF) and lymphotoxin (LT) alpha differentially modulate cellular sensitivity to TNF/LT-alpha cytotoxicity in L929 cells.
Targeting Pi3k In Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from interference with the cancer cells' ability to respond to stromal signals, as illustrated by the approved PI3Kd inhibitor idelalisib in B-cell malignancies. Inhibition of the leukocyte-enriched PI3Kd or PI3K. may unleash antitumor T-cell responses by inhibiting regulatory T cells and immune-suppressive myeloid cells. Moreover, tumor angiogenesis may be targeted by PI3K inhibitors to enhance cancer therapy. Future work should therefore also explore the effects of PI3K inhibitors on the tumor stroma, in addition to their cancer cell-intrinsic impact. Significance: The PI3K pathway extends beyond the direct regulation of cancer cell proliferation and survival. In B-cell malignancies, targeting PI3K purges the tumor cells from their protective microenvironment. Moreover, we propose that PI3K isoform-selective inhibitors may be exploited in the context of cancer immunotherapy and by targeting angiogenesis to improve drug and immune cell delivery. (C) 2016 AACR
- âŠ